Stroke Patients Given Epoetin In Trial Had Higher Mortality Rate, FDA Warns
This article was originally published in The Pink Sheet Daily
The off-label use is not expected to have commercial impact, analyst says.
You may also be interested in...
Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.
Agency uses new authority to mandate label changes by Amgen and J&J in areas where negotiations were unsuccessful.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.